Interstitial cystitis
Drug research and approvals for interstitial cystitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 23 studies of interstitial cystitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 23
- Trials authorized in Canada: 7
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting now
Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗- Aerobic Exercise and Connective Tissue Massage in Painful Bladder SyndromeNCT07839689 · Not applicable · Hacettepe University · starts Apr 30, 2026
- Early vs Delayed Intravesical Blad-Care During BCG TherapyNCT07495072 · Not applicable · BLAD-HYA Group · starts Nov 3, 2025
- Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial CystitisNCT04734106 · Early Phase 1 · Wake Forest University Health Sciences · starts Feb 18, 2025
- Acupuncture First for IC/BPSNCT06366269 · Not applicable · University Hospitals Cleveland Medical Center · starts Jan 21, 2025
- Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain…NCT06394830 · Phase 2 · Vaneltix Pharma, Inc. · starts Dec 13, 2024
- Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in…NCT06729151 · Not reported · Walter Reed National Military Medical Center · starts Nov 1, 2024
- Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical InstillationNCT06719232 · Not reported · Jahn Ferenc South Pest Teaching Hospital · starts Oct 1, 2024
- Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder SyndromeNCT06096597 · Phase 2 / Phase 3 · David Sheyn · starts Jul 24, 2024
- Pain Type and Interstitial Cystitis/Bladder Pain Syndrome TreatmentNCT06299683 · Not applicable · Vanderbilt University Medical Center · starts May 1, 2024
- Bladder Botox UTI Antibiotic ProphylaxisNCT06387329 · Phase 4 · Walter Reed National Military Medical Center · starts Apr 4, 2024
Drug pipeline
1 approved, 11 in phase 3, 14 in phase 2, 7 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Pentosan polysulfate sodium
- Amitriptyline
- Phase 3 Serotonin transporter inhibitor
- Rosiptor
- Phase 3 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator
- Certolizumab pegol
- Phase 3 TNF-alpha inhibitor
- Mycophenolate mofetil
- Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Omalizumab
- Phase 3 Ig epsilon chain C region inhibitor
- Estrogens, conjugated
- Phase 3 Estrogen receptor agonist
- Adalimumab
- Phase 3 TNF-alpha inhibitor
- Triamcinolone acetonide
- Phase 3 Glucocorticoid receptor agonist
- Mirabegron
- Phase 3 Beta-3 adrenergic receptor agonist
- Methenamine
- Phase 3 DNA inhibitor
- Gabapentin
- Phase 3 Voltage-gated calcium channel modulator
- Onabotulinumtoxina
- Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Lidocaine
- Phase 2 Sodium channel alpha subunit blocker
- Heparin
- Phase 2 Antithrombin-III activator
- Dimethyl sulfoxide
- Phase 2 Unknown
- Tanezumab
- Phase 2 Beta-nerve growth factor inhibitor
- Cyclosporine
- Phase 2 Cyclophilin A modulator
- Naltrexone
- Phase 2 Opioid receptors; mu/kappa/delta antagonist
- Gefapixant
- Phase 2 P2X purinoceptor 3 antagonist
- Fremanezumab
- Phase 2 Calcitonin gene-related peptide antagonist
- Interferon
- Phase 2
- Tipelukast
- Phase 2
- Rezatomidine
- Phase 2
- Ozone
- Phase 2
- PD-0299685
- Phase 2
- Cannabidiol
- Phase 1 Cannabinoid CB1 receptor negative allosteric modulator
- Peppermint oil
- Phase 1
- Sunobinop
- Phase 1
- Wax, emulsifying
- Phase 1
- Ferumoxytol
- Early phase 1 Unknown
Showing the 30 furthest along of 32 in trials.
How its trials ended
214 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 48 whose ending is known, 13% met their primary endpoint, 10% missed it and 77% stopped early.
- Completed, result not reported10850%
- Ongoing3617%
- Stopped: other or unclear2311%
- Status unknown2210%
- Met its primary endpoint63%
- Missed its primary endpoint52%
- Stopped: enrollment or feasibility42%
- Stopped: sponsor or business decision42%
- Stopped: lack of efficacy31%
- Stopped: funding21%
- Stopped: safety10%
Trials authorized in Canada
Newest first; search them all in Canada trials| Feb 25, 2022 | A multicenter, randomized, double-blind, placebo-controlled, parallel arm study to assess the safety and efficacy of a single treatment of botox®, followed by…Botox | AbbVie | Closed |
| Jul 3, 2020 | Efficacy and safety of fremanezumab for treatment of female patients with ic-bpsAjovy (fremanezumab) | Teva Pharmaceutical Industries | Pending |
| Jul 29, 2016 | The leadership 301 trial: a 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy…AQX-1125 | Aquinox Pharmaceuticals Inc | Closed |
| Jun 18, 2015 | A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial…Liris | AbbVie | Closed |
| May 14, 2015 | A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial cystitis with…Liris | AbbVie | Closed |
| May 30, 2013 | The leadership study: a phase II study to evaluate the efficacy and safety of AQX-1125 in subjects with interstitial cystitis/bladder pain syndrome mediated by…AQX-1125 | Aquinox Pharmaceuticals Inc | Ongoing |
| Apr 10, 2013 | A phase 2a multicenter, randomized, double-blinded, placebo-controlled study evaluating safety, tolerability and efficacy of liris® 400 mg in women with…Liris | Taris Biomedical Inc | Closed |
FDA orphan designations
Approved first, then open designations, newest first| Sep 26, 1996 | ElmironRelief of bladder pain or discomfort associated with interstitial cystitis. | Alza Corporation | Approved |
| Jun 13, 1991 | NifedipineTreatment of interstitial cystitis. | Fleischmann, Jonathan M.D. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA